Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Letermovir · Prevymis, AIC-246

Small molecule · Inhibitor of CMV DNA terminase complex · developed by Merck Sharp Dohme

Approved FDA, Nov 2017

MRK Developer

1 Registered trials

What is Letermovir?

Letermovir is a small-molecule inhibitor of CMV DNA terminase complex. It is also studied in liver transplant recipients.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Prevymis, AIC-246, MK-8228
Drug type: Small molecule
Targets: CMV DNA terminase complex
Mechanism: Inhibitor of CMV DNA terminase complex
Therapy area: Immunology, Infectious disease
Developer: Merck Sharp Dohme (MRK)
FDA status: Approved as Prevymis (November 8, 2017), NDA209939 · FDA label
UNII: 1H09Y5WO1F

✅ FDA-approved uses

Prophylaxis of CMV infection and disease in CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant
Prophylaxis of CMV disease in kidney transplant recipients at high risk (D+/R-)

From the indications section of the FDA label (version of Jan 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07706166	Phase 4	Kidney Transplant	Not yet recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Kidney TransplantLiver Transplant

More from Merck Sharp Dohme

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3 Favezelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Letermovir

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z